News Headline Summary

Blue Cross have changed their position on Vermillion's (VRML) OVA1 ovarian cancer test from medically necessary to investigational for all indications

Reaction details:

- VRML shares dipped 4.95% to USD 1.35 per share in the immediate reaction.

Print 17:48, 21 Dec 2012 - US Equities - Source: B4THESTREET.COM